Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tegaserod-associated ischemic colitis.

John K DiBaise1

  • 1Mayo Clinic Scottsdale, Scottsdale, Arizonia, USA. Dibaise.john@mayo.edu

Pharmacotherapy
|June 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fear, Feeding, and the Gut: Nutrition Support Considerations in Adults with ARFID and Gastrointestinal Symptoms.

Nutrients·2026
Same author

Short bowel syndrome-associated intestinal failure: diagnosis and prognosis.

Expert review of gastroenterology & hepatology·2026
Same author

Gut instinct: Navigating the landscape of parenteral support in short bowel syndrome.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition·2024
Same author

Relationship Functioning and Gut Microbiota Composition among Older Adult Couples.

International journal of environmental research and public health·2023
Same author

Short bowel syndrome: Complications and management.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition·2023
Same author

Short bowel syndrome: Recognizing unmet needs.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition·2023
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Tegaserod, a serotonin 5-HT4 receptor agonist, is linked to serious ischemic colitis cases in women with constipation-predominant irritable bowel syndrome, prompting labeling changes.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Internal Medicine

Background:

  • Tegaserod is a selective serotonin 5-HT4 receptor partial agonist.
  • It is prescribed for women diagnosed with constipation-predominant irritable bowel syndrome (IBS-D).
  • Post-marketing surveillance identified serious adverse events, including diarrhea and ischemic colitis.

Observation:

  • This report details a case of ischemic colitis in a patient undergoing tegaserod treatment.
  • The occurrence of ischemic colitis has led to updated physician warnings and prescription labeling for tegaserod.
  • The relationship between tegaserod, irritable bowel syndrome, and ischemic colitis is reviewed.

Findings:

  • Tegaserod use is associated with infrequent but serious reports of ischemic colitis.

Related Experiment Videos

  • The drug's mechanism of action may contribute to ischemic colitis development.
  • A causal link between tegaserod and ischemic colitis is suggested.

    • Implications:

    • Physicians should exercise caution when prescribing tegaserod, especially in patients with risk factors for ischemic colitis.
    • Further research is warranted to elucidate the mechanisms underlying tegaserod-induced ischemic colitis.
    • Updated drug labeling and warnings aim to improve patient safety and informed prescribing practices.